Page 1

IQVIA Contacts : Andrew Markwick , IQVIA Investor Relations ( andrew.markwick@iqvia.com ) +1.973.257.7144 Tor Constantino , IQVIA Media Relations ( tor.constantino@iqvia.com ) +1.484.567.6732 • • • . • IQVIA Reports First - Quarter Results ; Raises Full - Year 2021 Guidance Revenue of $ 3,409 million for the first quarter grew 23.8 percent year - over - year Adjusted EBITDA of $ 744 million for the first quarter increased 32.4 percent year - over - year GAAP Diluted Earnings per Share of $ 1.09 for the first quarter ; Adjusted Diluted Earnings per Share of $ 2.18 for the first quarter grew 45.3 percent year - over - year R & D Solutions contracted backlog of $ 23.2 billion grew 18.3 percent year - over - year ; next twelve months revenue from backlog increased to $ 6.5 billion , up 31.1 percent year - over - year Full - year 2021 guidance raised for revenue , Adjusted EBITDA and Adjusted Diluted EPS - RESEARCH TRIANGLE PARK , N.C. April 22 , 2021 – IQVIA Holdings Inc. ( " IQVIA ” ) ( NYSE : IQV ) , a leading global provider of advanced analytics , technology solutions , and clinical research services to the life sciences industry , today reported financial results for the quarter ended March 31 , 2021 . First - Quarter 2021 Operating Results Revenue for the first quarter of $ 3,409 million increased 23.8 percent on a reported basis and 21.4 percent at constant currency , compared to the first quarter of 2020. Technology & Analytics Solutions ( TAS ) revenue of $ 1,348 million grew 20.7 percent on a reported basis and 17.1 percent at constant currency . Research & Development Solutions ( R & DS ) revenue of $ 1,868 million grew 29.6 percent on a reported basis and 28.1 percent at constant currency . Excluding the impact of pass throughs , R & DS revenue increased 21.9 percent year - over - year on a reported basis . Contract Sales & Medical Solutions ( CSMS ) revenue of $ 193 million was lower by 1.5 percent on a reported basis and by 4.1 percent at constant currency . R & DS contracted backlog , including reimbursed expenses , grew 18.3 percent year - over - year to $ 23.2 billion at March 31 , 2021. The company expects approximately $ 6.5 billion of this backlog to convert to revenue in the next twelve months , representing growth of 31.1 percent compared to March 31 , 2020. The first - quarter contracted net book - to - bill ratio was 1.41x including reimbursed expenses and 1.41x excluding reimbursed expenses . For the last twelve months ended March 31 , 2021 , the contracted net book - to - bill ratio was 1.52x including reimbursed expenses and 1.45x excluding reimbursed expenses . " We had a record quarter , with strong double - digit growth across all key financial metrics and strong free cash flow conversion , " said Ari Bousbib , chairman and CEO of IQVIA . " Our business momentum continues to accelerate , with TAS and R & DS reporting exceptional organic growth rates in the quarter . As a result of this outstanding performance , and the sustained strength of our new business wins , we are raising our 2021 financial guidance . We expect demand for our differentiated clinical and commercial offerings will continue to grow beyond 2021 , on top of an increasingly favorable outlook for the life sciences industry . " First - quarter 2021 Adjusted EBITDA was $ 744 million , up 32.4 percent compared to the first quarter of 2020 . GAAP net income was $ 212 million , and GAAP diluted earnings per share was $ 1.09 . Adjusted Net Income was $ 425 million and Adjusted Diluted Earnings per Share was $ 2.18 , up 45.3 percent compared to the first quarter of 2020 . 1